Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OGEN .625 vs ALORA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.
Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.
Treatment of moderate to severe vasomotor symptoms due to menopause,Treatment of vulvar and vaginal atrophy due to menopause,Prevention of postmenopausal osteoporosis
Moderate to severe vasomotor symptoms due to menopause,Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prostate cancer (palliative),Breast cancer (palliative, in selected cases),Postpartum breast engorgement (prevention)
0.625 mg orally once daily
Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.
Estrone: 10-24 hours; equilin: 12-18 hours; terminal half-life supports once-daily dosing.
The terminal elimination half-life of estradiol is approximately 13-19 hours following transdermal administration, reflecting slow release from the skin depot and ongoing metabolism. This half-life allows for continuous hormone levels with once- or twice-weekly dosing.
Primarily metabolized in the liver via CYP3A4; undergoes first-pass metabolism including sulfation and glucuronidation. Estropipate is hydrolyzed to estradiol and then metabolized.
Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates (glucuronides and sulfates).
Renal (primarily as glucuronide and sulfate conjugates, ~50-80% of a dose), fecal (~10-20%), with enterohepatic recirculation.
Alora (estradiol transdermal system) is eliminated primarily via hepatic metabolism, with approximately 60% of a dose excreted in urine as glucuronide and sulfate conjugates, and about 40% excreted in feces via biliary elimination.
~50-80% bound to sex hormone-binding globulin (SHBG) and albumin.
Estradiol is approximately 97-99% bound to serum proteins, primarily sex hormone-binding globulin (SHBG) and albumin. The binding to SHBG is high affinity, while albumin binding is nonspecific and lower affinity.
Estrone: ~1-2 L/kg; indicates extensive tissue distribution.
The apparent volume of distribution (Vd) of estradiol is approximately 5-10 L/kg, indicating extensive distribution into tissues including breast, adipose, and reproductive organs. This large Vd reflects sequestration in adipose tissue and other estrogen-sensitive tissues.
Oral: ~30-50% due to first-pass metabolism; micronized formulation enhances absorption.
The bioavailability of estradiol from the transdermal system is approximately 10% compared to oral administration, due to avoidance of first-pass hepatic metabolism. The absolute bioavailability relative to intravenous is near 100%, as transdermal delivery provides direct systemic absorption.
No dose adjustment required for GFR ≥30 m L/min; insufficient data for GFR <30 m L/min, use with caution
No dose adjustment required for mild-moderate renal impairment (GFR >=30 m L/min). Not studied in severe impairment (GFR <30 m L/min); use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
Contraindicated in severe hepatic disease (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use lowest effective dose and monitor. No adjustment for mild (Child-Pugh class A).
Not indicated for use in pediatric patients
Not approved for use in pediatric patients. Safety and efficacy not established.
Use lowest effective dose; monitor for thromboembolic events and malignant neoplasms; no specific dose adjustment recommended
Use lowest effective dose and duration. Consider increased risk of cardiovascular events, thromboembolism, and malignancy. Starting dose 0.025 mg/day with gradual titration as needed.
Estrogens increase the risk of endometrial carcinoma in postmenopausal women. Also, estrogens should not be used to prevent cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis have been reported with estrogen-alone therapy.
Estrogens increase the risk of endometrial cancer. Unopposed estrogen increases the risk of endometrial hyperplasia and carcinoma. Adequate diagnostic measures, including endometrial sampling if indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
Increased risk of endometrial cancer; cardiovascular disorders (MI, stroke, VTE); probable dementia; breast cancer; gallbladder disease; hypercalcemia; fluid retention; visual abnormalities; hereditary angioedema; exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, SLE, and hepatic hemangiomas; hypothyroidism; elevated triglycerides; and hypersensitivity reactions.
Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism), probable dementia (increased risk in women ≥65 years), breast cancer, endometrial cancer, gallstones, hypertriglyceridemia, fluid retention, hypocalcemia, hereditary angioedema, and exacerbation of endometriosis.
Undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active or past history of venous thromboembolism; active or recent arterial thromboembolic disease (e.g., stroke, MI); liver dysfunction or disease; known hypersensitivity to estrogens; known protein C, protein S, or antithrombin deficiency; and pregnancy.
Undiagnosed abnormal genital bleeding, known/suspected pregnancy, known/suspected breast cancer (except in selected cases), known/suspected estrogen-dependent neoplasia, active DVT/PE or history of these conditions, active arterial thromboembolic disease, known protein C/protein S/antithrombin deficiency or other thrombophilic disorders, liver dysfunction or disease, known hypersensitivity to estradiol or any component.
Grapefruit juice may increase estrogen levels; avoid large quantities. No other significant food interactions.
No significant food interactions. Avoid grapefruit juice if on hormonal therapy as it may increase estrogen levels.
First trimester: Estrogens are associated with a potential risk of fetal genital tract abnormalities, including congenital anomalies such as hypospadias and vaginal adenosis. Use is contraindicated in pregnancy. Second and third trimesters: Exposure may increase risk of fetal urogenital tract abnormalities, and estrogens have been linked to an elevated risk of vaginal clear cell adenocarcinoma in female offspring. Overall, use is contraindicated throughout pregnancy due to known fetal risks.
ALORA (estradiol vaginal ring) is contraindicated in pregnancy. First trimester: estrogen exposure is associated with a risk of vaginal adenosis and clear cell adenocarcinoma in female offspring, as well as congenital anomalies including cardiac defects and limb reduction defects. Second and third trimesters: increased risk of fetal genital abnormalities and potential for long-term reproductive tract effects. Estrogens are not indicated for use during pregnancy.
Estropipate (ogen) is excreted into human breast milk. The milk-to-plasma ratio (M/P ratio) is not established in published literature. Exogenous estrogens may reduce milk production and quality, particularly in early postpartum. Use during breastfeeding is generally not recommended due to potential adverse effects on the infant, including jaundice and long-term effects on reproductive development. Alternative therapies should be considered.
Estradiol is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.1-0.2. ALORA may reduce milk production and quality due to estrogenic effects. Use during breastfeeding is not recommended. If used, monitor the infant for signs of estrogen exposure such as breast enlargement or vaginal bleeding.
Estropipate is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) are not relevant due to absolute contraindication. No dose adjustments are applicable as the drug should not be used.
ALORA is contraindicated in pregnancy; no dosing adjustments are applicable. The physiological increase in estrogen-binding proteins and hepatic clearance during pregnancy would theoretically reduce efficacy if used, but use is prohibited due to teratogenicity.
OGEN 0.625 mg (estropipate) is a conjugated estrogen tablet for hormone therapy. It may increase risk of endometrial cancer; use with progestin in women with intact uterus. Monitor for thromboembolic events. Not for prevention of cardiovascular disease or dementia. Avoid in pregnancy.
ALORA 0.03% estradiol vaginal cream is indicated for atrophic vaginitis. Apply 1-2 g daily for 2 weeks, then taper. May cause endometrial hyperplasia if used without progestin in women with intact uterus. Avoid in breast cancer history.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, chest pain, shortness of breath, or vision changes immediately.,Avoid smoking as it increases risk of blood clots.,Inform all healthcare providers that you are taking estrogen.,Regular breast exams and mammograms are recommended.
Use the measured applicator for correct dose.,Apply cream at bedtime for best absorption.,Wash applicator after each use with soap and water.,Report any abnormal vaginal bleeding immediately.,Do not use if allergic to estrogens.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OGEN .625 vs ALORA, answered by our medical review team.
OGEN .625 is a Estrogen that works by Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.. ALORA is a Estrogen that works by Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OGEN .625 and ALORA depend on the specific clinical indication. These are both Estrogen agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OGEN .625 is: 0.625 mg orally once daily. The standard adult dose of ALORA is: Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OGEN .625 and ALORA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OGEN .625 is classified as Category C. First trimester: Estrogens are associated with a potential risk of fetal genital tract abnormalities, including congenital anomalies such as hypospadias and vaginal adenosis. Use i. ALORA is classified as Category C. ALORA (estradiol vaginal ring) is contraindicated in pregnancy. First trimester: estrogen exposure is associated with a risk of vaginal adenosis and clear cell adenocarcinoma in fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.